A made-in-Canada approach to producing the world’s most commonly used medical isotope has received Health Canada approval, ushering in a new era for patients in Canada and around the world who rely on these isotopes for critical diagnostic procedures.
Fifteen BC Cancer clinicians and scientists have been named in Clarivate’s Highly Cited Researchers 2020 list announced last week. Each has been ranked in the top one per cent in their fields using a method of data and analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information at Clarivate.
For BC Cancer, those fields include clinical medicine, molecular biology and genetics, and cross-field a category which recognizes influence across several fields.
Reading cancer imaging tests may become more straightforward and informative for BC Cancer radiologists thanks to a new research partnership between BC Cancer and Microsoft’s AI for Health program. In this partnership, a group of data and computer scientists at Microsoft will be working alongside Dr. Arman Rahmim, senior scientist at the BC Cancer Research Institute (BCCRI), and Dr. Ivan Klyuzhin, research programmer at BCCRI. Together the team will be developing AI algorithms to assist radiologists and cancer researchers in detection and assessment of tumours in PET/CT images.
Approximately 835 people in British Columbia will be diagnosed with pancreatic cancer this year. While pancreatic cancer remains one of the most deadly cancers, new research recently published in Cell Reports Medicine has identified a new combination treatment that may overcome drug resistance in pancreatic cancer.
The Government of Canada, through the National Research Council (NRC), is helping businesses and academia work together. In a recent announcement, three BC Cancer researchers have received grant funding to foster new research projects which may lead to important breakthroughs.The funding, totalling over $370,000 combined, is being awarded to Drs. Dedhar, Lum and Holt for game-changing scientific discoveries and technological breakthroughs.
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a particularly devastating cancer commonly diagnosed in women in their twenties and often has a very poor prognosis. In a recent study, researchers with the BC Cancer Research Institute have uncovered a metabolic vulnerability present in SCCOHT cells which may be a target for future treatment options.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.